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Background: Lone atrial flutter (AFL) and atrial fibrillation (AF) are common and sometimes consequential cardiac
conduction disorders with a strong heritability, as underlined by recent genome-wide association studies that
identified genetic modifiers. Follow-up family-based genetic analysis also identified Mendelian transmission of
disease alleles. Three affected members were exome-sequenced for the identification of potential causative
mutations, which were subsequently validated by direct sequencing in the other 3 affected members. Taqman assay
was then used to confirm the role of any mutation in an independent population of sporadic lone AFL/AF cases.
Results: The family cluster analysis provided evidence of genetic inheritance of AFL in the family via autosomal
dominant transmission. The exome-sequencing of 3 family members identified 7 potential mutations: of these,
rs58238559, a rare missense genetic variant in the ATP-binding cassette sub-family B, member 4 (ABCB4) gene was
carried by all affected members. Further analysis of 82 subjects with sporadic lone AF, 63 subjects with sporadic lone
AFL, and 673 controls revealed that the allele frequency for this variation was significantly higher in cases than in the
controls (0.05 vs. 0.01; OR = 3.73; 95% CI = 1.16–11.49; P = 0.013).
Conclusions: rs58238559 in ABCB4 is a rare missense variant with a significant effect on the development of AFL/AF.
Keywords: Pedigree, Atrial flutter, Atrial fibrillation, SNPs, Exome-sequencing, ATP-binding cassette B4 (ABCB4)Background
Atrial flutter (AFL) is the second most common arrhythmia
after atrial fibrillation (AF). It is a heart rhythm disturbance
that results in the upper chambers of the heart beating up
to five-times faster (usually 240–350 atrial contractions/
minute) than normal. There is a close interrelationship be-
tween AFL and AF, with AFL of variable duration preced-
ing the onset of AF in many instances [1].
AFL is significantly associated with alcohol intake in
patients under 60 years of age [2]. A study based on a
US population determined that the incidence rates for
AFL ranged from 5 per 100,000 in those less than 50
years old to 587 per 100,000 in those older than 80 years* Correspondence: apuca@unisa.it
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unless otherwise stated.old [3]. Moreover, AFL was 2.5-times more common in
men, and the risk of developing AFL increased with con-
comitant hyperthyroidism, valvular diseases, myocardial
infarction, and congestive heart failure [4].
Hypertension and diabetes were the only significant
independent cardiovascular risk factors for AF when
controlling for age and other predisposing conditions in
38-year follow-up data from the Framingham Study [5].
Other evidence suggested that AF in parents increases
the future risk of AF in their offspring and that the risk
increased when the parent developed AF before age 75
years [4].
Genome-wide association studies (GWAS) have been
recently conducted for AFL/AF. The first GWAS identi-
fied a genetic modifier for AF and AFL in an Icelandic
population [6]: it found an association for AFL/AF with
the rs2200733 polymorphism in the PITX2 gene on. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This association was replicated in other populations, in-
cluding the population we are investigating [7]. Others
studies identified variants in ZFHX3 [8], KCNN3 [9],
SCN5A [10], and a further six loci [11] associated with
AF. All these studies interrogated hundreds of thousands
to millions of common polymorphisms genome-wide
with the potential of impacting the AF phenotype, but
with only a small effects size [12]. These variants explain
only a small percentage of the high heritability estimated
for AF. The presence of rare variants with large effects
size are not sufficiently covered by GWAS, and this
could explain the missing heritability of AF [12].
Thus, genetic analysis on familial clusters of AFL/AF
could disclose rare variants with large size effects [13].
Several studies have reported rare variants in familial
cases of AF in genes encoding cardiac gap junctions, sig-
naling molecules, and ion channels, supporting a role
for cardiac depolarization–repolarization in susceptibility
to AF. Most AF-related genes encode potassium and so-
dium channels [13]. Of these, mutations in the sodium
ion channel gene SCN5A, at 3p22.2 (OMIM#*600163),
have been correlated with idiopathic AF [14] and pos-
sibly also with AFL, conduction diseases, Brugada syn-
drome, and sudden cardiac death [15]. Among the
potassium channel genes, KCNQ1 (OMIM#*607542),
previously identified as causative for long and short QT
syndromes, has been also identified as responsible for a
familial form of AF [16].
Here, we report a study on a pedigree containing 6
AFL-affected family members. Exome sequencing of 3
affected individuals, followed by direct sequencing of theFigure 1 Pedigree of the family affected by atrial flutter/fibrillation. G
indicated with Arabic numerals. Solid squares (males) and circles (females)
and gray symbols indicate unknown disease status. Diamonds indicate not
subjects. Diagonal lines indicate dead subjects. Arrows identify the analyze
allele while M indicates the heterozygotic subjects for rs58238559 variant. Aother affected members and of 3 unaffected members, in-
dicated a possible causative role of a missense mutation in
the ATP-binding cassette sub-family B, member 4 gene
(ABCB4). This mutation was significantly enriched in




The presentation of 3 brothers (subject IDs: IV:1, IV:2,
and IV:3) for treatment of AFL led to the construction
of a four-generation pedigree (Figure 1) [17]. The pedi-
gree contained 43 subjects (23 males and 20 females). A
brief medical history was obtained for each subject
(where possible) in order to identify known risk factors
for AFL [3]. A summary of the subjects with docu-
mented cardiovascular abnormalities is provided in
Table 1 (cases are described in the Methods section).
No direct parent-to-child transmission of AFL has
been documented in the literature. However, in the
present case study, AFL was identified in a woman
(III:2) and in 3 (60%) of her 5 children (IV:1, IV:2, and
IV:3). AFL was also documented in a nephew (IV:7) and
a cousin (III:6). The father of IV:7 died from a cerebral
ictus at 49 years of age, possibly as a complication of
AFL. Furthermore, AFL was documented in the 3rd and
4th generations only, likely because of poor diagnosis
and inadequate reporting of this dysrhythmia in earlier
generations. The almost complete absence of any known
risk factor(s) for AFL [3] other than hypertension in 3
(50%; III:2, III:6, and IV:1) of the 6 subjects with AFL
suggested that this family has a heritable susceptibilityeneration is indicated with roman numerals, and individual ID is
indicate affected subjects, open symbols indicate unaffected subjects,
-relevant subjects and the numbers within them are the number of
d subjects. WT indicates homozygotic carriers of rs58238559 major
ges are given beneath the individual’s ID number.
Table 1 Summary of Pedigree Members with Documented Cardiovascular Abnormalities
Generation Subject ID Age Sex Risk factor Cardiovascular abnormality
III 2 86 Female Hypertension Atrial flutter
III 6 80 Male Hypertension; alcohol abuse Atrial flutter
IV 1 67 Male Hypertension; smoking Atrial flutter
IV 2 64 Male Smoking Atrial flutter
IV 3 63 Male Smoking Atrial flutter
IV 7 57 Male — Atrial flutter
IV 9 52 Male — Myocardial infarction
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dysrhythmia are compatible with autosomal dominant
genetic transmission.
Exome sequencing in familial AFL cases
To identify the causative gene mutation, we sequenced
the whole exome of 3 affected subjects of the family, be-
longing to the third (III:6) and fourth (IV:1 and IV:7)
generations (complete data sets of exome sequencing re-
sults are available in the on-line Additional file 1). The
filtered results indicated that: a) none of the previously
identified causative genes harbored rare missense muta-
tions in the 3 sequenced subjects; and b) 6 damaging,
non-synonymous single-nucleotide variations (SNVs)
and 1 stop–gain mutation were shared by the 3 subjects
(Table 2).
We checked the involvement of these mutations in
AFL by sequencing the DNA of the other affected mem-
bers (III:2, IV:2, and IV:3) and of 3 unaffected members
(III:3; III:10 and IV:9) of the family. This additional se-
quencing analysis was conducted because of the small
number of subjects analyzed by exome sequencing. Of
the 7 variations identified, only rs58238559 (A599G;
NM_000443.3) in the ABCB4 gene was in heterozygosity
in all affected individuals (Figure 2). The father (III:4) of
affected individual IV:7 – who died of a cerebral ictus at
49 years of age, possibly as a complication of AFL – carried
a copy of the minor allele (G) of rs58238559 (his living,
healthy wife is wild type, and the affected child is a G car-
rier), so he probably transmitted AFL to one of his twoTable 2 SNVs Identified by Exome Sequencing and Validated
Variant coordinates SNP ID Gene V
chr7:123599641 rs199703625 SPAM1 n
chr11:1769211 — IFITM10 n
chr7:81601108 rs78086631 CACNA2D1 n
chr7:87082273 rs58238559 ABCB4 n
chr15:76225153 — FBXO22 n
chr11:117257921 — CEP164 n
chr2:27522165 rs146448995 TRIM54 s
*UCSC Genome Browser database. MAF =minor allele frequency.children. Of note, descendants of II:6 (III:10 and IV:9),
whose family branch is not affected by the disease, are not
rs58238559 carriers. On the other hand, IV:4 and IV:5,
who are offspring of III:2 and who have no manifestation
of the disease (as yet), carry the rs58238559 minor allele in
heterozygosity. This could explain the variable onset of
disease.
The rs58238559 single-nucleotide polymorphism (SNP)
is located in the ABCB4 gene on chr7:87082273, and de-
termines the nucleotide variation A599G (NM_000443.3)
(Figure 2), producing the amino acid change Thr175Ala
(NP_000434.1). Of note, a Thr175Val variation at the same
position has been previously related to gallbladder disease
in a sporadic case [18], while ABCB4mutations are usually
associated with familial forms of the disease [19]. The
medical history of the AFL-affected pedigree did not dis-
close any gallbladder disease. Taken together, the above
data leads to the speculation that ABCB4 variants at pos-
ition 175 produce a modest genetic predisposition for gall-
bladder disease, whereas Thr175Ala produces a familial
autosomal form of lone AFL.
AFL/AF case–control validation
To corroborate our finding on the role of the ABCB4 gene
variation in AFL/AF, we analyzed a cohort of AFL/AF
cases and controls, part of which we previously used to
validate rs2200733 in AFL/AF [7]. The criteria of adopting
AFL/AF cases comes from previous evidences of shared
genetic risk factors, despite are two distinct clinical entities.
No deviations from the Hardy–Weinberg equilibrium wereby PCR Products Sequencing
ariation Nucleotide changes MAF* (%)
on-synonymous SNV A– > G 0.100
on-synonymous SNV C– > T —
on-synonymous SNV G– > A 0.270
on-synonymous SNV A– > G 0.652
on-synonymous SNV C– > A —
on-synonymous SNV G– > T —
top–gain mutation G– > T 0.022
Figure 2 Sequencing electropherograms. Electropherograms of control (upper) and atrial flutter/fibrillation-affected (lower) subjects with
rs58238559 in the ABCB4 gene. Heterozygosity is indicated by the presence of two peaks corresponding to T and C (in the box).
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that the frequency of the mutated allele was significantly
higher in cases than in the controls (0.05 vs. 0.01; OR =
3.73; 95% confidence interval =1.16–11.49; P = 0.013). Of
note, there was sufficient statistical power to detect the re-
ported association, according to the frequencies in cases
and controls and sample sizes observed (1-β = 0.81). With
respect to the rest of the cohort, individuals with the
Thr175Ala amino acid change in ABCB4 have a 3.75-fold
increase in the probability of developing atrial fibrillation/
flutter. We also repeated the analysis separating AFL from
AF to evaluate their contribution to the association and we
found very similar carrier frequencies in the two cohorts
(AFL N= 63; 4,76% carriers, AF N = 78; 4,88% carriers), in-
dicating a similar genetic effect in the two populations.
Limitations
Despite the filtering cut off that we adopted of MAF > 1%
is relatively high and would increase the chance of false
positive results [20] we believe to have avoided this limita-
tion by replicating the data in an independent cohort. One
additional limitation is the lack of covariates in our ana-
lysis, as for drinking behavior, even if we are not aware of
any bias in recruiting cases and controls (i.e. both arms of
the study should share same habits).
Discussion
Arrhythmia of the atria is a common disorder with an
important impact on morbidity and mortality [21]. It in-
creases tremendously the risk of complications, such aspulmonary embolism and stroke. Understanding the
underlying molecular mechanisms of AFL/AF is, there-
fore, very important. To this end, genetic approaches
aimed at uncovering the pathogenesis of this disease are
very useful. A recent GWAS identified common poly-
morphisms able to modify the risk of AF, while family-
based studies have disclosed many mutations causative
of familial and sporadic forms of lone AF [13].
The present study of a family with a strong clustering
of AFL-affected members has found that the rs58238559
SNP in ABCB4, which produces a Thr175Ala amino acid
change, is associated with AFL/AF. Moreover, follow-up
analysis has found significant enrichment of rs58238559
in sporadic AFL/AF cases. Thus, we propose ABCB4 as
a previously unrecognized disease-related gene for lone
AF/AFL, and that it should be further investigated in re-
lation to AFL/AF epidemiology and pathophysiology.
Functionally, ABCB4 belongs to a family of lipid trans-
porters and is specifically involved in transport of phos-
phatidylcholine (PC) across membranes [22]. ABCB4 is
mainly expressed in liver, but also in heart, adrenal
gland, striated muscle, spleen, and tonsil [23]. Interest-
ingly, ABCB4-/- knock-out mice had low secretion of PC
into the bile, leading to cholestasis and liver fibrosis [24].
In humans, ABCB4 associates with progressive familial
intrahepatic cholestasis [19], and intrahepatic cholestasis
during pregnancy is a common disorder associated with
fetal AF [25]. Thus, we propose a pathogenic mechanism
whereby the mutation of ABCB4 generates AF/AFL ei-
ther directly in the heart or indirectly through the liver
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cholestasis and AF could also explain why cholestasis
has been reported in AF patients under therapy [26-28].
Conclusions
We have found genetic evidence for a role of ABCB4 in fa-
milial lone AF and sporadic lone AFL/AF. This is sup-
ported by pre-existing data on the role of ABCB4 in
cholestasis and by the correlation of cholestasis with fetal
arrhythmia and adult AF/AFL. Further genetic analyses in
humans as well as cardiac phenotype characterization of




The unusual presentation of 3 brothers (subject IDs:
IV:1, IV:2, and IV:3 described below) for treatment of
AFL led to the construction of a four-generation pedi-
gree (Figure 1) [17]. The pedigree contained 43 subjects
(23 men and 20 women). A brief medical history was ob-
tained for each subject (where possible) in order to iden-
tify known risk factors for AFL [3].
Subject IV:1 A 67-year-old male diagnosed with com-
mon AFL approximately 5 years ago. Medical history
identified the presence of hypertension and a history of
smoking. Absence of structural anomalies in the heart or
cardiac disease suggested lone AFL. This subject was in-
effectively managed by antiarrhythmic (AA) drug ther-
apy (flecainide and enalapril), but recently underwent
catheter ablation to create bi-directional conduction
block across the cavotricuspid isthmus (CTI). The sub-
ject continues to be arrhythmia free following the cath-
eter ablation procedure.
Subject IV:2 A 64-year-old male diagnosed with com-
mon AFL approximately 1 year ago. Apart from smoking,
medical history did not identify the presence of any
chronic conditions or risk factors for AFL. Absence of
structural anomalies in the heart or cardiac disease sug-
gested lone AFL. This subject was ineffectively managed
by AA drug therapy (flecainide and sotalol), but recentlyTable 3 Primer Sequences Used in the Validation Analysis







TRIM54 TTCATGCTTAAGGTCCACCTCunderwent catheter ablation to create bi-directional con-
duction block across the CTI. The subject continues to be
arrhythmia free following the catheter ablation procedure.
Subject IV:3 A 63-year-old male diagnosed with com-
mon AFL approximately 1 year ago. Apart from smoking,
medical history did not identify the presence of any
chronic conditions or risk factors for AFL. Absence of
structural anomalies in the heart or cardiac disease sug-
gested lone AFL. This subject was ineffectively managed
by AA drug therapy (propafenone), but recently under-
went catheter ablation to create bi-directional conduction
block across the CTI. The subject continues to be
arrhythmia free following the catheter ablation procedure.
Subject IV:7 A 57-year-old male diagnosed with com-
mon AFL approximately 4 years ago. Medical history did
not identify the presence of any chronic conditions or
risk factors for AFL. This subject continues to be rea-
sonably managed by AA drug therapy alone (flecainide),
but continues to experience arrhythmic symptoms.
Subject III:2 The 86-year-old mother of IV:1, IV:2, and
IV:3 also has AFL, which was diagnosed approximately
25 years ago. Medical history identified hypertension,
but no other risk factors. Of the 5 offspring of this sub-
ject, 3 (60%) developed AFL by the 6th decade of life.
Subject III:6 An AFL-affected cousin of III:2. Medical
history for this cousin identified excessive alcohol con-
sumption and hypertension as risk factors.
In addition, 145 sporadic AFL/AF patients (N = 63 with
AFL, and N = 82 with AF) were enrolled for a case–control
validation study. To this end, consecutive symptomatic AF
and common AFL patients referred to our institution for
electrophysiological studies and catheter ablation were en-
rolled. The patients were anti-arrhythmic-drugs-free a
week before admission. The study was conducted in ac-
cordance with the ethical principles that have their origins
in the Declaration of Helsinki. Written informed consent
was obtained from all participants for the current study
that was approved by the IRCCS MultiMedica Review
Board CE/CE/92/2013/LDC. Written consent form for
data publication was obtained from all involved subjects.
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sessment was performed without knowledge of genotype.
Exome sequencing
Exomic regions of genomic DNA of 3 affected pedigree
subjects (subject IDs: III:6, IV:1, and IV:7) were enriched
using either the TruSeq™ Exome Enrichment Kit (Illumina)
or the Agilent Haloplex Exome kit based on DNA digestion
and capture. Exomes were barcoded and sequenced at mul-
tiple sites on the Illumina HiSeq1000 platform, and either
2 × 76-bp (TruSeq) or 2 × 100-bp (Haloplex) PE libraries,
using TruSeq SBS Kit v3–HS (Illumina) reagents and a
TruSeq PE Cluster kit v.3-cbot-HS flow cell. Average cover-
age for all the experiments was 70x and at least 20× for
89% of the target. Paired sequencing reads were aligned to
the reference genome (UCSC, hg19 build) using BWA [29]
and sorted with SAMtools [30] and Picard (http://broadin-
stitute.github.io/picard/). Post-alignment processing (local
realignment around insertions-deletions and base recalibra-
tion), SNV, and small insertions-deletions (ins-del) call-
ing were performed with Genome Analysis Toolkit
(GATK) [31] with parameters adapted to the haloplex-
generated sequences. The called SNV and ins-del vari-
ants produced with both platforms were annotated
using ANNOVAR [32].
Data filtering
The results were first filtered to eliminate common vari-
ants (MAF > 1%), variants with low quality score, and
variants not shared by all analyzed affected subjects,
when covered. Additional frequency filters were used by
comparing internal databases of whole exome sequen-
cing data (n = 300). Prioritization was also made based
on MAF frequency.Validation analysis
Genomic DNA of the remaining affected subjects and of 3
unaffected subjects was amplified with polymerase chain
reaction (PCR), following standard methods, for selected
single-nucleotide polymorphisms (SNPs). The amplified
fragments were purified with Wizard SV Gel and PCR
Clean-Up System (Promega) and were sequenced to iden-
tify mutations associated with AFL. Primer sequences and
amplification temperatures are listed in Table 3.
Taqman assay
DNA was extracted from peripheral blood (QIAamp DNA
Blood Midi kit, Qiagen) and genotyped with Taqman
assays on an ABI 7900HT Real Time PCR (Applied
Biosystems). For the screening, we used a probe for
rs58238559. The reactions were performed using Geno-
typing Master Mix (Applied Biosystems). Data analysiswas performed with Sequence Detection Systems (Applied
Biosystems).
Statistics for case–control analysis
Differences in genotype distribution between cases and
controls were tested with two-sided Fisher’s Exact test, as
implemented in the R statistical software tool (http://www.
r-project.org/). Deviations from the Hardy–Weinberg
equilibrium were tested with the PLINK software tool [33].
The threshold for identifying statistically significant associ-
ations was set at a P-value < 0.05.
Additional file
Additional file 1: Complete data sets: the file lists the results of
exome sequencing analysis.
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